Stock Events

Stock Events

Talphera 

$1.0900
65
+$0.12+12.36% Thursday 20:00

Statistics

Day High
1.09
Day Low
0.96
52W High
1.57
52W Low
0.38
Volume
781,299
Avg. Volume
-
Mkt Cap
50.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.21
-0.16
-0.1
-0.04
Expected EPS
-0.0625
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-26.01MNet Income

Analyst Ratings

3.00Average Price Target
The highest estimate is 3.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TLPH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a leading global biopharmaceutical company that competes with Talphera in the development and marketing of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. is a global pharmaceutical corporation which competes directly with Talphera in various therapeutic areas, including oncology, rare diseases, and immunology.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Talphera in the discovery, development, and delivery of innovative medicines that help patients prevail over serious diseases.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, competing with Talphera in the fields of antiviral drugs, cancer, and other diseases.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie Inc. is a research-based biopharmaceutical company that develops and markets advanced therapies, competing with Talphera in areas such as immunology and oncology.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. is one of the world's leading biotechnology companies, competing with Talphera in developing innovative human therapeutics, including treatments for serious illnesses.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson is a comprehensive healthcare company that competes with Talphera through its pharmaceutical segment, developing drugs for a wide range of medical conditions.
Novartis
NVS
Mkt Cap292.07B
Novartis AG is a global healthcare company based in Switzerland that competes with Talphera in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche competes with Talphera in the pharmaceutical sector, particularly in oncology and virology.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company that competes with Talphera in developing and commercializing prescription medicines for several therapeutic areas, including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

About

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
Show more...
CEO
Mr. Vincent J. Angotti
Employees
13
Country
United States
ISIN
US00444T2096

Listings

STU
DE
R5XA.STU
MU
DE
R5XA.MU
XNAS
US
TLPH
F
DE
R5XA.F

0 Comments

Share your thoughts

FAQ

What is Talphera stock price today?▼
The current price of TLPH is $1.09 USD — it has increased by +12.36% in the past 24 hours. Watch Talphera stock price performance more closely on the chart.
What is Talphera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Talphera stocks are traded under the ticker TLPH.
Is Talphera stock price growing?▼
TLPH stock has risen by +24.86% compared to the previous week, the month change is a +31.59% rise, over the last year Talphera has showed a +123.82% increase.
What is Talphera market cap?▼
Today Talphera has the market capitalization of 50.8M
When is the next Talphera earnings date?▼
Talphera is going to release the next earnings report on August 19, 2026.
What were Talphera earnings last quarter?▼
TLPH earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.07 USD resulting in a +40% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Talphera revenue for the last year?▼
Talphera revenue for the last year amounts to 0 USD.
What is Talphera net income for the last year?▼
TLPH net income for the last year is -26.01M USD.
How many employees does Talphera have?▼
As of June 19, 2026, the company has 13 employees.
In which sector is Talphera located?▼
Talphera operates in the Health & Wellness sector.
When did Talphera complete a stock split?▼
The last stock split for Talphera was on October 26, 2022 with a ratio of 1:20.
Where is Talphera headquartered?▼
Talphera is headquartered in San Mateo, United States.